---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-025128"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T17:16:19.765732+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma reports Q1 net loss $52.2M; LYL314 RMAT designation and pivotal trial on track

## Summary
- Net loss of $52.2M (GAAP) vs $60.7M YoY; non-GAAP net loss $46.3M vs $37.5M YoY.
- Cash, equivalents and marketable securities $330.1M as of Mar 31, 2025; sufficient into 2027.
- R&D expenses $43.4M, G&A $14.0M; workforce reduction and closure of West Hills facility impacted costs.
- LYL314 granted RMAT designation by FDA for relapsed/refractory DLBCL in third-line setting.
- Pivotal trial of LYL314 in third-line expected mid-2025; second-line pivotal trial by early 2026.

## SEC filing metadata
- accession: 0001628280-25-025128
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/0001628280-25-025128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/lyel-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-025128
- JSON: https://secwatch.observer/filing/0001628280-25-025128.json
- Plain text: https://secwatch.observer/filing/0001628280-25-025128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.